Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short vs standard duration therapy for uncomplicated enterococcal bacteremia
2023-508456-18-00Phase 4Authorised
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación
- Start
- Apr 2024
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of piperacillin + tazobactam, vancomycin, linezolid, amoxicillin, amoxicillin + clavulanate and 2 more in Enterococcus faecalis bacteremia and Enterococcus faecium bacteremia (2 arms), sponsored by Fundación Pública Andaluza para la Gestión de la Investigación. Primary endpoint: Clinical success at test-of-cure (TOC) in the intention-to-treat per-protocol population (ITTP). Planned start Apr 2024; status: authorised.
02
Drugs
piperacillin + tazobactamvancomycinlinezolidamoxicillinamoxicillin + clavulanate
03
Conditions
Enterococcus faecalis bacteremiaEnterococcus faecium bacteremia
Beyond the preview
Go deeper on 2023-508456-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508456-18-00.